Otsuka America Pharmaceutical Inc.
Otsuka America Pharmaceutical Inc.
News Article | November 10, 2016
OncLive® is proud to announce the 2016 Giants of Cancer Care®, an esteemed group of 10 innovators in oncology research and clinical practice who have made landmark contributions to the field of oncology and set the stage for future advances. The winners were announced today at 11:35 a.m. and will be honored at tonight’s awards celebration from 5 to 7 p.m. at the New York Marriott Marquis, which is being held during the 34th Annual CFS Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®. Now in its fourth year, the Giants of Cancer Care® campaign celebrates the achievements of leading physicians and researchers who have devoted their time, talent and resources to improving care for patients and their families affected by cancer. Recipients of the award demonstrate the qualities that distinguish them from others: unlimited selflessness, compassion for their patients and a desire to understand and develop life-changing treatments against a disease that affects so many. “Giants of Cancer Care® award winners are helping to move the field of oncology forward through their commitment to innovative and groundbreaking contributions in cancer treatment and research. Our winners' achievements not only give cancer patients and their families hope, but they also inspire future generations of researchers and practitioners to continue advancing toward a cure for this disease,” says Michael Hennessy, Jr., president of Mike J. Hennessy Associates Inc., which produces OncLive®. Nominated by the oncology community, all finalists are vetted by an elite five-member advisory board of world-renowned oncologists. The finalists in each category are then voted on by an 80+ member selection committee comprising the nation's leading physicians in the oncology space. The winners represent 10 categories: breast cancer, community outreach and education, gastrointestinal cancer, genitourinary cancer, hematologic malignancies, lung cancer, melanoma, radiation oncology, scientific advances and surgical oncology. Hematologic Malignancies – James F. Holland, M.D., Icahn School of Medicine at Mount Sinai, New York, N.Y. According to the National Cancer Institute, almost 1.7 million new cases of cancer will be diagnosed in 2016, and nearly 600,000 people will die from the disease. However, the number of people living beyond a cancer diagnosis is rising and is expected to reach almost 19 million by 2024. Giants of Cancer Care® honorees are at the forefront of the battle against this disease. The Giants of Cancer Care® program is overseen by an advisory board that includes its chairman Dr. Maurie Markman, from Cancer Treatment Centers of America, and members Dr. Patrick Borgen, Maimonides Hospital; Dr. George D. Demetri, Dana-Farber Cancer Institute/Harvard Cancer Center; Dr. Hope S. Rugo, University of California, San Francisco/Helen Diller Family Comprehensive Cancer Center; and Dr. Heather Wakelee, Stanford University Medical Center. Every year for the past 33 years, the annual CFS Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® has brought together more than 2,000 oncologists, hematologists, radiation oncologists, immunologists, pharmacists, oncology nurses, nurse practitioners, physician assistants and case managers to learn about state-of-the-art treatments across solid and hematologic malignancies and diverse clinical scenarios. At the 34th Annual CFS Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®, leading clinical innovators in virtually every tumor subspecialty will continue to provide expert insights on new developments in cancer therapeutics. Domestic and international nominations for the 2017 Giants of Cancer Care® are open now through March 20, 2017, and may be submitted online at http://www.giantsofcancercare.com/nominate. Self-nominations are permitted and encouraged. The Giants of Cancer Care® Advisory Board will determine finalists in each category, and a selection committee of more than 90 oncologists will vote to select the 2017 winners. The Class of 2017 Giants of Cancer Care® inductees will be announced in Chicago on June 1, 2017. The 2016 Giants of Cancer Care® program was sponsored by Bayer Health Care, Merck, Puma Biotechnology, Incyte and Otsuka America Pharmaceutical Inc. About OncLive® OncLive® is a digital platform for practicing oncologists that offers oncology professionals information to help them provide the best patient care. OncLive.com is the official website for Michael J. Hennessy Associates Inc.'s Oncology Specialty Group, which publishes OncologyLive®, Oncology Nursing News®, Oncology Business Management™ and more. Michael J. Hennessy Associates Inc. is a full-service health care communications company offering education, research, medical media, curetoday.com and CURE® magazine, the largest consumer publication focused entirely on cancer. CURE® combines science and humanity to make cancer understandable and reaches patients, cancer centers and advocacy groups.
Castillo J.J.,Brown University |
Vincent M.,Otsuka America Pharmaceutical Inc |
Justice E.,BioScience Communications
Oncologist | Year: 2012
Hyponatremia, a common electrolyte abnormality in oncology practice, may be a negative prognostic factor in cancer patients based on a systematic analysis of published studies. The largest body of evidence comes from small-cell lung cancer (SCLC), for which hyponatremia was identified as an independent risk factor for poor outcome in six of 13 studies. Hyponatremia in the cancer patient is usually caused by the syndrome of inappropriate antidiuretic hormone (SIADH), which develops more frequently with SCLC than with other malignancies. SIADH may be driven by ectopic production of arginine vasopressin (AVP) by tumors or by effects of anticancer and palliative medications on AVP production or action. Other factors may cause hypovolemic hyponatremia, including diarrhea and vomiting caused by cancer therapy. Hyponatremia may be detected on routine laboratory testing before or during cancer treatment or may be suggested by the presence of mostly neurological symptoms. Treatment depends on several factors, including symptom severity, onset timing, and extracellular volume status. Appropriate diagnosis is important because treatment differs by etiology, and choosing the wrong approach can worsen the electrolyte abnormality. When hyponatremia is caused by SIADH, hypertonic saline is indicated for acute, symptomatic cases, whereas fluid restriction is recommended to achieve a slower rate of correction for chronic asymptomatic hyponatremia. Pharmacological therapy may be necessary when fluid restriction is insufficient. The orally active, selective AVP receptor 2 (V 2)-receptor antagonist tolvaptan provides a mechanism-based option for correcting hyponatremia caused by SIADH or other conditions with inappropriate AVP elevations. By blocking AVP effects in the renal collecting duct, tolvaptan promotes aquaresis, leading to a controlled increase in serum sodium levels. © AlphaMed Press.
Offord S.,Otsuka America Pharmaceutical Inc.
Journal of medical economics | Year: 2013
To compare hospitalizations and incidence of relapses among patients with schizophrenia initiating long-acting injectable (LAI) antipsychotics vs oral antipsychotics. Patients with schizophrenia initiating LAI antipsychotics or oral antipsychotics (index events) were identified from large databases (MarketScan; Truven Health Analytics, CA), containing commercial and Medicare healthcare claims and their pre-index (12-month baseline period) and post-index (12-month follow-up period) hospitalizations and relapse rates were compared. Descriptive and bivariate statistics were utilized to compare demographics, clinical characteristics, and hospital resource usage among cohorts. Multivariate analysis was used to evaluate the impact of initiating LAI vs oral antipsychotics on differences in the number of hospitalizations and length of stay (LOS) between follow-up and baseline periods. Commercially insured patients initiating LAI antipsychotics (n = 394) had significant reductions in inpatient healthcare usage after initiating antipsychotic therapy: mean number (±standard deviation) of all cause hospitalizations (1.60 ± 1.66 vs 0.70 ± 1.20, p < 0.001), LOS (16.9 ± 20.7 vs 6.6 ± 14.4 days, p < 0.001), schizophrenia-related hospitalizations (1.03 ± 1.26 vs 0.43 ± 0.86, p < 0.001), associated LOS (12.3 ± 17.7 vs 4.8 ± 12.8 days, p < 0.001). Patients initiating LAI vs oral antipsychotics (n = 2610) had significantly greater reductions during the follow-up period vs baseline period in the mean number of all cause hospitalizations (-0.90 ± 1.77 vs 0.02 ± 1.49, p < 0.001), LOS (-10.3 ± 23.2 vs 0.7 ± 16.7 days, p < 0.001), schizophrenia-related hospitalizations (-0.60 ± 1.37 vs 0.05 ± 0.99, p < 0.001) and associated LOS (-7.5 ± 20.7 vs 0.6 ± 12.5 days, p < 0.001). These results were further supported by multivariate analyses in which patient characteristics were taken into consideration. This study attempted to minimize the impact of differences in patient characteristics by having patients serve as their own controls in the before vs after comparison followed by multivariate regressions, however one still may not be able to account for all confounders in this non-randomized study population. Patients with schizophrenia who initiated LAI vs oral antipsychotics experienced reductions in hospitalizations and schizophrenia relapses after drug initiation, which may be indicative of improved disease management.
Otsuka America Pharmaceutical Inc. | Date: 2012-01-25
The present invention relates to a method of applying a fluid, comprising introducing a fluid to a substantially hydrophilic foam (112); and depositing a desired portion of the fluid onto a targeted area.
Otsuka America Pharmaceutical Inc. | Date: 2015-11-06
Systems and methods for healthcare system administration are described. Data may be acquired through a variety of methods and predictive analytics and indicators may be determined. Tools used may include membership cards with information concerning a consumer of healthcare services and/or an activity monitor for determining levels of activity. A caregiver check-in tool may provide additional data regarding the status of the caregiver and/or the consumer.
Otsuka America Pharmaceutical Inc. | Date: 2015-01-14
A system for applying a fluid, comprising a packet containing a fluid, the packet comprising first and second opposing packet sides defining therebetween a sealed space containing the fluid; a frangible area configured to rupture upon compressing the packet to release the fluid from the packet; and a collapsibility feature enabling the first packet side of the packet to invert from a convex position to a concave position upon compressing the packet so that the formerly sealed space is substantially completely collapsed; and an applicator device comprising: a handle having a proximal end and a distal end, the handle comprising a receptacle at the proximal end of the handle, the receptacle configured to receive the packet of the fluid and facilitate expulsion of the fluid from the packet; a base disposed at the distal end of the handle and configured to direct flow of the released fluid and including a distal opening; and an applicator pad configured to be coupled to the base, in fluid communication with an interior portion of the receptacle via the distal opening of the base.
Otsuka America Pharmaceutical Inc. | Date: 2013-08-13
Otsuka America Pharmaceutical Inc. | Date: 2015-09-23
A preparation for determining levodopa metabolic capacity, comprising as an active ingredient a levodopa in which at least one of the carbon or oxygen atoms is labeled with an isotope, wherein the preparation is capable of producing isotope-labeled CO_(2) after administration to a mammalian subject. A method for determining levodopa metabolic capacity in a mammalian subject, comprising the steps of administering a preparation according to claim 1 to a mammalian subject, and measuring the excretion behavior of an isotope-labeled metabolite excreted from the body. A method for determining the efficacy of a dopamine decarboxylase inhibitor to treat a medical condition in a first mammalian subject, the method comprising (a) administering to the first subject the dopamine decarboxylase inhibitor and a levodopa in which at least one of the carbon or oxygen atoms is labeled with an isotope, wherein the levodopa is capable of producing isotope labeled CO_(2); (b) determining the level of levodopa metabolic capacity by measuring isotope labeled CO_(2) produced in the first subject; and (c) comparing the level of levodopa metabolic capacity of the first subject to level of a reference standard levodopa metabolic capacity, wherein a similarity in the level of levodopa metabolic capacity of the first subject compared to level of a reference standard levodopa metabolic capacity indicates that the dopamine decarboxylase inhibitor is effective to treat the medical condition in the first mammalian subject.
Otsuka America Pharmaceutical Inc. | Date: 2013-10-16
The application pertains to a system (10) for applying a fluid, comprising a packet (12) containing a fluid, the packet comprising first and second opposing packet sides (38) defining therebetween a sealed space (40) containing the fluid; a frangible area configured to rupture upon compressing the packet to release the fluid from the packet; and a collapsibility feature enabling the first packet side of the packet to invert from a convex position to a concave position upon compressing the packet so that the formerly sealed space is substantially completely collapsed; and an applicator device (14) comprising: a handle (16) having a proximal end and a distal end, the handle comprising a receptacle (18) at the proximal end of the handle, the receptacle configured to receive the packet of the fluid and facilitate expulsion of the fluid from the packet; a base (22) disposed at the distal end of the handle and configured to direct flow of the released fluid and including a distal opening; and an applicator pad (26) configured to be coupled to the base, in fluid communication with an interior portion of the receptacle via the distal opening of the base.
Otsuka America Pharmaceutical Inc. | Date: 2016-05-10
Software for use by radiologists and treating healthcare providers to stage and monitor kidney diseases and disorders.